Tectonic Therapeutic reports Q1 2026 non-GAAP EPS -$1.34 (-44% YoY) on revenue $0, missing EPS estimates
- Company says $236.9M cash funds its operations into Q4 2028.
- Q1 2026 revenue was $0, beating analyst revenue estimates for the quarter.
- Company highlights advancement of TX45 and TX2100 clinical programs in its first-quarter 2026 update.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.